Broome Oncology

NIH study finds long-term increased risk of cancer death following common treatment for hyperthyroidism

Findings from a study of patients who received
radioactive iodine (RAI) treatment for hyperthyroidism show an association
between the dose of treatment and long-term risk of death from solid cancers,
including breast cancer. The study, led by researchers at the National Cancer
Institute (NCI), part of the National Institutes of Health, was published July
1, 2019 in JAMA Internal Medicine.

“We identified a clear dose–response
relationship between this widely used treatment and long-term risk of death
from solid cancer, including breast cancer, in the largest cohort study to date
of patients treated for hyperthyroidism,” said Cari Kitahara, Ph.D., of NCI’s
Division of Cancer Epidemiology and Genetics, lead author of the study . “We
estimated that for every 1,000 patients treated currently using a standard
range of doses, about 20 to 30 additional solid cancer deaths would occur as a
result of the radiation exposure.”

RAI, which has been used widely in the United
States for the treatment of hyperthyroidism since the 1940s, is one of three
commonly used treatments for hyperthyroidism. The other two are anti-thyroid
drugs, which have been rising in popularity, and surgical treatment, which is
used least often.

The new findings are from a long-term
follow-up study of a large cohort of people with hyperthyroidism (mainly
Graves’ disease) who were treated with radiation between 1946 and 1964, the
Cooperative Thyrotoxicosis Therapy Follow-up Study. In the new analysis — which
included nearly 19,000 people from the original cohort, all of whom had
received RAI and none of whom had had cancer at study entry — the researchers
used a novel, comprehensive method of estimating radiation doses to each organ
or tissue. Most of the radiation is absorbed by the thyroid gland, but other
organs like the breast and stomach are also exposed during treatment. 

The researchers observed positive
dose–response relationships between the dose absorbed by an organ and mortality
from cancer at that site. The relationship was statistically significant for
female breast cancer, for which every 100 milligray (mGy) of dose led to a 12%
increased relative risk of breast cancer mortality, and for all other solid
tumors considered together, for which relative risk of mortality was increased
by 5% per every 100 mGy.

Based on these findings, the researchers
estimated that for every 1,000 patients aged 40 years with hyperthyroidism who
were treated with the radiation doses typical of current treatment, a lifetime
excess of 19 to 32 radiation-attributable solid cancer deaths would be
expected.

According to the researchers, in the United
States, about 1.2% of the population has hyperthyroidism, and women are much
more likely to develop the condition than men. Therefore, the findings for
breast cancer mortality are particularly relevant for the large population of
women treated for hyperthyroidism, Dr. Kitahara said.

“We found the increased risks of death from
solid cancer overall and from breast cancer more specifically to be modest, but
RAI is still a widely used treatment for hyperthyroidism,” she said. “It’s
important for patients and their physicians to discuss the risks and benefits
of each available treatment option. The results of our study may contribute to
these discussions.”

The researchers wrote that additional research
is needed to more comprehensively assess the risk–benefit ratio of radiation
versus other available treatment options for hyperthyroidism. Furthermore,
because the types of anti-thyroid drugs administered to patients in the
original cohort were different from those prescribed more recently, the
researchers wrote that more studies are needed to evaluate long-term health effects
of current anti-thyroid drugs, including in comparison to RAI treatment.

About the National
Cancer Institute (NCI):
 NCI leads
the National Cancer Program and NIH’s efforts to dramatically reduce the
prevalence of cancer and improve the lives of cancer patients and their
families, through research into prevention and cancer biology, the development
of new interventions, and the training and mentoring of new researchers. For
more information about cancer, please visit the NCI website at cancer.gov or call NCI’s
contact center, the Cancer Information Service, at 1-800-4-CANCER
(1-800-422-6237).

Copyright © 2019 CancerConnect. All Rights Reserved.